Ogivri

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Ogivri treats breast cancer and stomach cancer that is HER2 positive. The HER2 test determines if your cancer is HER2-positive before taking Ogivri.

Ogivri Overview

Reviewed: January 15, 2018
Updated: 

Ogivri is a prescription medication used to treat breast cancer and stomach cancer where a receptor called HER2 is overexpressed. It may be used alone or in combination with other medications. 

Ogivri belongs to a group of drugs called monoclonal antibodies. These work by stopping the growth of cancer cells.

Ogivri is a biosimilar (closely related) product to Herceptin (trastuzumab).

This medication comes in injectable form and is given into the vein (IV) by a healthcare provider once every week or once every 3 weeks.

Common side effects of Ogivri include headache, fever, and diarrhea.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Ogivri Drug Class

Back to Top

Ogivri is part of the drug class:

Ogivri FDA Warning

Back to Top

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY 

Cardiomyopathy

  • Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens.
  • Evaluate left ventricular function in all patients prior to and during treatment with Ogivri. Discontinue Ogivri treatment in patients receiving adjuvant therapy and withhold Ogivri in patients with metastatic disease for clinically significant decrease in left ventricular function.

Infusion Reactions; Pulmonary Toxicity

  • Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt Ogivri infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue Ogivri for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

Embryo-Fetal Toxicity

  • Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.